Incyte Stock News

Although U.S. stock futures traded higher this morning after recording losses on Tuesday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company''s prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga''s insider transactions platform. Incyte The Trade: Full story available on Benzinga.com

With equity prices soaring to record levels, many execs have cashed out. Here are the insider stocks where execs are cashing in.

For the past half dozen years, investors couldn't care less about a company's balance sheet.

Here is another look at Exelon, Incyte and other stocks that Wall Street analysts expected little from in this past week.

Wall Street analysts are constantly releasing and updating reports on stocks across their respective coverage universes.

Image provided by Pexels This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. In early December, Oncolytics Biotech Inc. (NASDAQ: ONCY ) presented the latest news on its Phase 2 study of the breast cancer treatment it’s developing at the 2021 San Antonio Breast Cancer Symposium . The biotech company has been working on its lead drug candidate, pelareorep, in partnership with a handful of industry leaders in the cancer therapy space. IRENE, a Phase 2 study investigating the use of Oncolytics’ pelareorep in combination with Incyte Corp. ’s (NASDAQ: INCY ) retifanlimab, was first announced in June 2020, and the initial doses were administered to patients in late August 2020. Now, Dr. Mridula George of Rutgers Cancer Institute of New Jersey has presented the latest safety data at the annual breast cancer symposium. Full story available on Benzinga.com

Incyte <> has extended its post-market losses on Wednesday despite recording better than expected revenue for Q4 2021.Its blockbuster JAK inhibitor, JAKAFI/JAKAVI…

Incyte Corporation (NASDAQ:INCY) price is hovering lower on Wednesday, February 09, dropping -2.60% below its previous close. >> 5 Best Growth Stocks for 2022 << >> 5 Best Growth Stocks for 2022 << A look at todays price movement shows that the recent level at last check reads $70.07, with intraday deals fluctuating between $67.90 These Numbers Show Just How Powerful Incyte Corporation (NASDAQ: INCY) Stock Is Read More »

Incyte (NASDAQ: INCY ) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 1 2 1 0 Last 30D 0 0 0 1 0 1M Ago 0 1 1 0 0 2M Ago 0 0 0 0 0 3M Ago 0 0 1 0 0 These 4 analysts have an average price target of $74.25 versus the current price of Incyte at $68.65, implying upside. Below is a summary of how these 4 analysts rated Incyte over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of … Full story available on Benzinga.com

BEP, GTES, and INCY have been added to the Zacks Rank #5 (Strong Sell) List on February 9, 2022

Incyte Corporation''s (NASDAQ: INCY ) Q4 adjusted EPS reached $0.10 , compared to $0.93 posted a year ago. Analysts had estimated $0.86. Sales increased 9.3% Y/Y to $862.85 million, ahead of the consensus of $813.40 million. The Company''s operating expenses increased 20.3% to $752.12 million, with the cost of sales up 21%, R&D costs up 16%, and SG&A costs Full story available on Benzinga.com

Incyte Corporation (NASDAQ:INCY) Q4 2021 Earnings Conference Call February 8, 2022 8:00 AM ET Company Participants Christine Chiou – Head-Investor Relations Hervé Hoppenot – Chairman,…

Incyte's (INCY) earnings miss, but revenues surpass estimates in the fourth quarter on higher royalty revenues and increased Jakafi sales.

Incyte press release (INCY): Q4 EPS of $0.10 may not be comparable to consensus of $0.86.Revenue of $862.5M (+9.2% Y/Y) beats by $49.12M.Total product and royalty revenues of $813…

Incyte Earnings Miss, Revenue Beats In Q4